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Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We
report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
in the presence of a previously undiagnosed connective tissue disease.*is article includes a literature review of pregnancy-related
cases of acquired factor VIII deficiency. We also reviewed various therapeutic approaches for the management of the acquired
factor inhibitor which include achieving hemostasis and elimination of the inhibitor via immunosuppressive agents. *is case
report describes the rare presentation of acquired factor VIII deficiency related to pregnancy and highlights the importance of
considering a factor VIII inhibitor in the differential diagnosis of patients who present with bleeding and prolonged PTTduring
the peripartum and postpartum periods.
1. Introduction
Acquired factor VIII deficiency is a rare bleeding diathesis
caused by the development of autoantibodies against clotting
factor VIII [1].*e annual incidence of the disorder is between
1.3 and 1.5 per million [1]. Apart from reproductive-aged
women during pregnancy and postpartum periods, acquired
factor VIII deficiency typically occurs after the fifth decade of
life [2]. Patients affected with acquired factor VIII deficiency
present with severe or life-threatening bleeding episodes in the
absence of previous bleeding predisposition. Bleeding severity
varies ranging from simple dermatological manifestations such
as petechiae and ecchymoses to internal bleeding [3] Acquired
factor VIII deficiency has been associated with several un-
derlying conditions such as malignancy, immunological dis-
orders, perinatal period, and variousmedications. Although the
association with underlying disorders has been reported, most
of the cases remain idiopathic.
2. Case Presentation
A 24-year-old Hispanic pregnant woman, gravida 2 para 1,
was admitted for gross hematuria without precipitating
factors at 29 weeks of gestation. *e patient reported that
this was the first episode of hematuria and had no prior
history of bleeding during her previous pregnancy or oth-
erwise. *e patient’s review of systems was significant for an
erythematous, maculopapular, nonpruritic rash, occurring
intermittently on the lower extremities since age 13. *e
patient had never been given a formal diagnosis but noted
that the rash also occurred during her first pregnancy, re-
solved spontaneously, and recurred about 2 weeks prior to
the current admission. *e patient denied family history of
hemophilia, von Willebrand disease, or autoimmune con-
ditions such as rheumatoid arthritis, systemic lupus eryth-
ematosus, scleroderma, or Hashimoto’s thyroiditis. *e
patient endorsed episodes of photosensitivity but denied
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constitutional symptoms, arthralgia, oral ulcers, myalgia,
pleuritic chest pain, xerostomia, keratoconjunctivitis sicca,
or any other significant symptoms. On physical examina-
tion, the patient had bilateral upper extremity and lower
back large ecchymoses, a palpable purpura on the anterior
aspect of the right thigh, bilateral knees, and hips, and
postinflammatory hyperpigmentation on the distal aspect of
lower extremities. Laboratory tests (Table 1) showed a
prolonged PTT of 92.1 s (RI: 24.3–36.7 s). Subsequent
workup revealed negative antiphospholipid panel including
negative pus anticoagulant, cardiolipin antibodies, and beta-
2 glycoprotein 1 antibodies. *e von Willebrand factor was
present in adequate amounts. *ere was a significantly
decreased factor VIII level of <1% (RI: 50–180%), and PTT
failed to correct with the addition of fresh plasma (mixing
studies) which suggested the presence of an inhibitor.
Bethesda assay was positive at 74.9U (RI: 0.6U) which
confirmed a high titer factor VIII inhibitor. Further workup
revealed a positive antinuclear antibody with high titer by
ELISA and positive SS-A and SS-B antibodies. Urinalysis
showed proteinuria of 858mg/24 h. Double-stranded DNA
and anti-Smith antibodies were negative. Complement C3
and C4 were present in normal amounts. *e patient was
diagnosed with acquired factor VIII deficiency and pre-
sumed systemic lupus erythematosus (SLE). She was initially
treated with DDAVP 30mcg intranasally along with pred-
nisone 45mg BID (1mg/kg a day in divided doses) while in
our facility. *e patient was transferred to a tertiary center
for a higher level of care where she received IVIG (intra-
venous immune globulin) 1 gm/kg for 2 days along with
porcine factor VIII. She was discharged from the hospital on
a prednisone taper. *e patient was followed closely by a
maternal-fetal medicine specialist and a hemophilia spe-
cialist. *e patient later delivered a healthy baby girl at 36
weeks via vaginal delivery without complications. At the
three-year follow-up, the patient remains in remission, and
her daughter has been without any cardiac problems or
bleeding diathesis. She was advised against future pregnancy.
3. Discussion
Acquired factor VIII deficiency associated with pregnancy
most commonly occurs during the peripartum and post-
partum period and rarely occurs before pregnancy. *e
cause and timing remain unclear, but many studies speculate
that it is due to the complex immunological changes that
occur during pregnancy. Some sources have theorized that
the development of the inhibitor is due to sensitization of the
mother’s immune system to fetal factor VIII during previous
pregnancies; however, some patients who acquire an in-
hibitor to factor VIII develop the inhibitor in the first
pregnancy (Table 2). *e inhibitor autoantibody that is
produced in patients with acquired factor VIII deficiency
attaches to a specific subunit of factor VIII, the C2 domain,
which results in diminished procoagulant activity and
subsequent bleeding [16]. *is is like the formation of
neutralizing antibodies against factor VIII in 25% of patients
with hemophilia A who are transfused with plasma-derived
or recombinant factor VIII. In the rare event of clinical
manifestations during pregnancy, such as in our patient, the
presence of factor VIII autoantibodies also puts the fetus at
risk of bleeding due to the maternofetal transplacental
passage of IgG antibodies. To date, there are less than fifty
reported cases of the maternal transplacental passage of the
inhibitor resulting in acquired factor VIII deficiency in the
fetus. Although rare, it is important to counsel the patient on
the possibility of these risks [17].*ere is no current accurate
way to determine the severity of bleeding in patients with
factor inhibitors based solely on titer levels. Studies have
shown that inhibitors to factor VIII are cleared in a non-
linear manner, thus resulting in an underestimation of
bleeding risk in some patients [18].
Acquired factor VIII deficiency occurs most commonly
in primigravid women at 2-3 months postpartum. *ese
patients typically present with soft tissue bleeding; however,
vaginal bleeding, hemarthrosis, and hematuria have been the
presenting symptoms in 13–18% of the reported cases [3].
Although our patient was gravida 2, she delivered her first
child 2.5 months prior to the conception that resulted in her
Table 1: Laboratory results.
Parameter Patient Referencerange
PT 11.8 s 9.8–12.6 s
INR 1.05 0.87–1.15
PTT 92.1 s 24.3–36.7 s
Coagulation factor VIII activity <1% 50–180%
Factor VIII inhibitor titer 74.9 BU <0.6 BU
vWF Ag 190% 50–217%
vWF ristocetin cofactor 122% 42–200%
vWF Ag, multimeric Normal
PTT-La screen 80 s <40 s
Hexagonal phase confirm Negative
DRVVT screen 22 s <45 s
DNA ds Ab 0.9 IU/mL <10 IU/mL
RNP 70 0.3U/mL <7.0U/mL
Rheumatoid factor quantitative 44.6 IU/mL <14.0 IU/mL
ANA >32.0 ratio >1.0 ratio
Cardiolipin Ab IgG <14GPL < or� 14
Cardiolipin Ab IgM <12GPL < or� 14
B2-glycoprotein IgM Ab <9GPL < or� 20
B2-glycoprotein IgG Ab <9GPL < or� 20
Anticentromere antibody <0.4U/mL <7.0U/mL
Jo 1 antibody <0/3U/mL <7.0U/mL
Scl 70 antibody <0.6U/mL <7.0U/mL
Smith antibody (Sm) <0.8U/mL <7.0U/mL
SS-A/Ro antibody >240U/mL <7.0U/mL
SS-B/La antibody 97U/mL <7.0U/mL
U1RNP antibody 0.6U/mL <7.0U/mL
Complement C3 174mg/dL 87–200mg/dL
Complement C4 20mg/dL 19–52mg/dL
Immunoglobulin A 242mg/dL 66–443mg/dL
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Table 2: Review of the literature.
Article Citation Presentation Findings Outcome
41 Michielset al. [4]
37 y/o G1P1 presented 4 months




Treated with prednisone taper of 1mg/kg
with remission within 2 months while on
20mg/d without recurrence at 5-year f/u.
22 y/o G3P3 presented 7 months
postpartum with menorrhagia and
bleeding after tooth extraction.
FVIII: 0.01–0.02U/
mL
FVIII inhibitor: 12 BU
Treatment with cyclophosphamide 100mg/
day (0.7mg/kg/d) without inhibitor
disappearance; however, spontaneous
remission developed 10 months later after
discontinuing medication. Subsequent
pregnancy without bleeding diathesis.
31 y/o G2P2 presented 2 months
postpartum with muscle and soft tissue
bleeding, menorrhagia, ecchymoses, and
hemarthrosis.
FVIII: <0.01U/mL
FVIII inhibitor: 24 BU
Treated with 4000U human factor VIII,
prednisone 1mg/kg/d for 6 weeks, and
cyclophosphamide 2mg/kg/d concomitantly
from the 3rd to 6th week of prednisone
treatment, with a 5-day course of high-dose
gamma-globulin at 0.5 g/kg/day. Recurrence
of the inhibitor with removal of agents
resulting in IVIG being initiated. Remission
at 28 months.
24 y/o G2P1A1 presented after delivery of





Treated with 1mg/kg prednisone for 3 weeks
without remission. Five years later presented
with FVIII 600 BU and thus 10KU of
cryoprecipitate. At 24 years after treatment,
the patient still had not achieved remission.
38 Coller et al.[5]
22 y/o primigravid woman presented with





FVIII inhibitor: 15 BU
vonWillebrand factor:
90%
Treated with 60mg prednisone daily, became
free of inhibitor within months, and had a
successful second pregnancy without any
subsequent bleeding diathesis.
6 Chaari et al.[9]




FVIII inhibitor: 64 BU
Treatment began with initial surgical
intervention for evacuation of hematoma but
was complicated by bleeding into the
abdominal cavity and genitalia. *e patient
was given recombinant FVIIa and activated
prothrombin complex concentrates. Due to
symptom progression, the patient started on
prednisone alone for 3 days followed by
cotherapy with cyclophosphamide without
symptom improvement. *e patient passed
away PPD 2/2 hemorrhagic shock.
5 Seethalaet al. [7]
36 y/o woman presented with PPH s/p








Received factor VII and desmopressin.
Treated with methylprednisolone, cytoxan,
and plasmapheresis with appropriate decline
in PTT but was discontinued because of sepsis
prior to discharge.*e patient was readmitted
for bacteremia and succumbed to severe
sepsis.
4 Kotani et al.[8]
31 y/o G1P1p developed postpartum
hemorrhage after delivery.
A female neonate developed subcutaneous
hemorrhage on dorsum of hand on day 1of
life s/p routine blood draw secondary to











Treatment for 31 y/o F consisted of 19U
PRBCS, 51U FFP, steroid pulse therapy, and
3 vials of factor VII during hospital course
and discharged on 30mg/day of
prednisolone. 10 months postpartum PTT
WNL without any further complications.
Neonate required no treatment and factor
VIII, and PTT returned to baseline at
postnatal month 4.
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current pregnancy. As the immunology of pregnancy poses a
conundrum, the presence of an untreated autoimmune
condition could have potentially interfered in the dynamic of
antibody formation and clearance in our patient.
*e isolated elevated PTT that failed to correct with the
mixing study in the context of bleeding is suggestive of the
inhibitor rather than lupus anticoagulant with latter trig-
gering clotting events. Laboratory testing was negative for
the lupus anticoagulant, but factor VIII activity was
significantly decreased at less than 1%. Bethesda assay was
positive at 74.9U confirming the presence of an inhibitor to
factor VIII. A unique aspect of our case was the importance
of recognizing the presentation of a previously undiagnosed
connective tissue disorder.
*e patient reported intermittent erythematous rash
reminding of purpura as well as photosensitivity since age
13, without any formal evaluation or diagnosis. Additional
testing during current pregnancy showed the presence of
Table 2: Continued.
Article Citation Presentation Findings Outcome
35 Chaari et al.[6]
31 y/o woman presented with several areas
of ecchymoses over lower extremities




Treated with prednisone and rituximab.
8 Porteouset al. [10]
32 y/o primigravid woman developed





FVIII inhibitor: 15 BU
Treated with 1mg/kg/day (60mg)
prednisolone, 5 doses of recombinant FVIIa
360 IU, 2 doses of DDAVP 0.3 µg/kg, 20U
PRBCs, tranexamic acid 1 g daily over 20 days
with continued bleeding. Bleeding was
controlled with bilateral internal pudendal
artery embolization. Maintenance therapy
was achieved with prednisolone 60mg and
tranexamic acid 500mg tds.
23 Sebastianet al. [11]
25 y/o F with a history of secondary APS in
the setting of SLE and acquired factor VII
inhibitor at 10 weeks of gestation
developed retroperitoneal bleeding. Prior
to current conception, the patient was
symptomatic having suffered from several
areas of ecchymoses on extremities,
episcleritis, and urticaria and having been












Treatment consisted of methylprednisolone
IV, recombinant factor VII, prednisone 1mg/
kg, and cyclosporine 250mg/day. *e patient
consented to terminate pregnancy.
Continued maintenance therapy with
cyclosporine 200mg/day, chloroquine
250mg/day, and methylprednisolone.
7 Rodrigueset al. [12]
34 y/o primigravid F presented PPD forty
with complaints of spontaneous
hematomas on extremities and
intramuscular bleeding on the back,
forearms, ankle, and thighs.
APTT: 62/<38 sec
FVIII: 3.5%




Treated with prednisone 1mg/kg/d plus
tranexamic acid. *e patient had remission of
the disease with normalization of FVIII
without the presence of the inhibitor in ∼2
years.
29 Lee et al. [13]
18 y/o F primigravid presented 9 months
postpartum with painful swelling of knees







Treated with activated prothrombin complex
concentrate and FEIBA anti-inhibitor
coagulant complex at a dose of 50–100 units/
kg q12 h. Corticosteroids were considered but
not indicated due to remission of symptoms.
39 Azam et al.[14]
26-year-old multiparous woman presented
PPD 2 with hemoperitoneum following
lower segment C-section.










Treated with prednisone 60mg/day initially
with taper and initiation azathioprine.
2 Qian et al.[15]
35-year-old PPD 48 with chest pain and






Treated with aPCC, human factor VIII
concentrates, corticosteroids, and plasma. At
6 months, no recurrence.
4 Case Reports in Rheumatology
positive ANA, SS-A, and SS-B antibodies in addition to
proteinuria, suggesting a diagnosis of SLE [19].
In addition to potential bleeding occurrence in the fetus,
the possible passive transplacental transfer of maternal anti-
SS-A and SS-B IgG antibodies incurs the risk of neonatal
lupus [20]. *ese presented a double risk for our patient that
could have potentially increased morbidity.
*e phenomenon that resulted in developing an inhibitor
to factor VIII could represent a concerted occurrence of
undiagnosed SLE as an autoimmune situation and the short
interpregnancy interval between the patient’s prior and
current pregnancy and the hormonal changes associated. As
the development of factor VIII inhibitors typically occurs in
the 2-3 postpartum period, the patient became pregnant
around the same interval, and the amplification of the process
leading to high-titer pathogenic antibodies could have been
caused by immunological processes of both undiagnosed SLE
and occurrence of subsequent pregnancy. Flares of SLE with
the characteristic antibody production that characterize the
disease occur frequently in the postpartum period.
*e immunology of pregnancy in SLE poses a para-
doxical juncture of immune tolerance required to insure the
viability of semiallogenic graft and the disturbance of the
tolerance characteristic of SLE.*emost important immune
alteration is related to the function of Treg cells. *e number
or the functionality of Treg cells is diminished in a disease
characterized by loss of immune tolerance such as SLE,
whereas the immune tolerance of the fetus is insured by Treg
in a normal pregnancy. Tregs’ presence is correlated with the
pregnancy outcome. Lower Tregs are associated with
pregnancy complications. Moreover, the immunological
processes of pregnancy are complicated by the confrontation
of two separate immune systems—the maternal immune
system and the fetal-placental immune system [21].
4. Literature Review
Our literature review identified fifteen cases of acquired factor
VIII deficiency associated with pregnancy with patient’s ages
ranging between 18 and 37 years. *e literature indicates that
most cases of acquired factor VIII inhibitors develop after the
first pregnancy and typically between 2 and 3 months
postpartum. Based on our literature review, we did note that
several of the patients developed acquired factor VIII in-
hibitors after delivering their first child; however, most pa-
tients developed postpartum hemorrhage within days of
delivery [5, 7–10]. *ere were other primigravid cases where
the patient developed acquired factor VIII inhibitors, but
symptoms did not manifest until 2–9 months postpartum
[4, 12, 15, 22]. Still, there were cases of acquired factor VIII
deficiency in women after their second pregnancy [14, 17] and
third pregnancy [4]. *ere did not seem to be any correlation
with the gravid status of the patient and clinical outcomes. Of
the fifteen cases reviewed, two patients died from compli-
cations related directly to the acquired factor deficiency in the
setting of hemorrhagic shock [9] and indirectly secondary to
sepsis in the setting of immunosuppression for eradication
therapy [20]. *ese two women were aged 19 and 36, re-
spectively, without other comorbid conditions and had initial
inhibitor levels within the 50–60BU range. An important
aspect of each of the aforementioned cases is that each patient
had significant vaginal bleeding on presentation. In the
former case, the patient presented with a large vaginal he-
matoma with intra-abdominal bleeding, and the latter de-
veloped uncontrolled vaginal bleeding for which she delayed
treatment for due to travel between the United States and
Mexico. It is unclear whether the prompt intervention could
have improved outcomes in these patients, but it is important
to consider the acquired factor VIII inhibitor as a differential
in a patient with persistent vaginal bleeding during or after
pregnancy. Of note, there were three patients (including our
case) who developed an acquired factor deficiency prior to
delivery [6, 11]. As mentioned previously, our patient de-
veloped the inhibitor during her second pregnancy. However,
she had a short interval between her first and second preg-
nancy. One of the cases of acquired factor deficiency prior to
delivery was in a patient with an underlying diagnosis of SLE
[11]. During our literature search, we did not identify other
cases reported of concomitant acquired factor deficiency in
pregnant patients with underlying connective tissue diseases.
As noted, our patient had an eventful delivery; however, the
aforementioned patient had to terminate the pregnancy due
to retroperitoneal bleeding which increased the risk for
mortality for both patient and fetus.
Regarding the titer level and severity of bleeding, there
appeared to be a higher requirement for blood products,
worsening of bleeding diathesis, and, in some cases, worse
outcomes with a Bethesda titer >100 BU [4, 8, 9, 11]. In one
of the cases, the patient inhibitor level increased from the
initial level of 64 BU to a level as high as 132 BU. As pre-
viously mentioned, this patient died due to hemorrhagic
shock on postpartum day 8 [9]. Likewise, the case of ac-
quired factor VIII concomitantly with SLE resulted in a
massive retroperitoneal bleed.*is patient had an initial titer
of 614 BU; however, the patient was able to successfully clear
the inhibitor although she did have to terminate pregnancy
due to the risk of worsening complications if she continued
to term [11]. Moreover, Michiels et al. described a case of a
young woman who delivered a stillborn and subsequently
developed postpartum hemorrhage with titers as high as
625 BU [4]. *is patient did not receive remission at follow-
up visits 24 years later despite immunosuppressive therapy.
Lastly, Kotani et al. described a case of postpartum hem-
orrhage with an initial titer level of 458 BU. *is patient
along with her neonate developed complications; however,
after the patient received several blood products including
nineteen packed red blood cells, fifty-one units of fresh
frozen plasma, 4.8mg of factor VIIa, and pulse steroid
therapy, the patient developed remission [8]. Previous
studies note that severity of bleeding does not correlate with
the titer level; however, our literature review shows that the
severity of bleeding is at least correlated with the titer level of
the inhibitor level which reaches as high as 100 BU.
Remission was achieved in most patients by a two-step
process aimed at controlling the bleeding and eliminating
the inhibitor. Our literature review showed that several
patients were treated with some combinations of either
desmopressin, factor eight inhibitor bypassing activity
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(FEIBA), recombinant human factor VIIa, or recombinant
porcine factor VIII concentrate, tranexamic acid, or some
other blood products including packed red blood cells or
fresh frozen plasma. Several agents were used for eradication
of the inhibitor including prednisone, methylprednisolone,
cyclophosphamide, rituximab, and azathioprine. *e Eu-
ropean Acquired Hemophilia Registry (EACH 2) reported
42 documented cases of acquired factor VIII deficiency
associated with the peripartum period out of the total 501
documented cases. Of the 42 cases, 74% of patients acquired
complete remission with first-line immunosuppressive
treatment with all women being alive at the last follow-up
visit. To date, there has not been a registry developed in the
United States.
5. Learning Points
Acquired factor VIII hemophilia secondary to the coagu-
lation factor inhibitor autoantibody is a rare condition that
can be associated with pregnancy and the peripartum period.
When it does occur during pregnancy, it most often occurs
postpartum but can rarely appear before delivery. *e pa-
tients present with a large sweep of bleeding manifestations
that can pose diagnostic and management challenges. Ele-
vated PTT that fails to correct by adding fresh plasma
suggests the presence of the inhibitor and should trigger
further workup. As cases are extremely rare, increased
awareness and further studies are needed so that prompt
intervention can be achieved.
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